Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

DIY tirzepatide, internet detective work and insurance appeals: The lengths 3 people are going to for weight loss drugs. Natalie Rahhal. July 2, 2025 at 7:00 AM. Copied; ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Eli Lilly and Company is conducting a clinical study titled ‘Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in ...

Tirzepatide was first approved for use in the US in May 2022, when it received an indication for adult patients with type 2 diabetes. 1 Indications for chronic weight management and sleep apnea ...

This study included 10,193 individuals who initiated tirzepatide without a T2D diagnosis, of whom 3470 had a 6-month post-index follow-up and were included in the AOM-eligible cohort.